000			03956nam a2200433 i 4500
003			ESmaUEC
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
040			_aES-MaUEC _bspa _cES-MaUEC
336			_aTexto _btxt _2rdacontent
710	2		_aSpringerLink (Online service) _9106996
999			_c109358 _d109358 _x1
001			109358
005			20230102113412.0
008			190506s2019 si | o |||| 0|eng d
020			_a9789811335402
024	7		_a10.1007/978-981-13-3540-2 _2doi
050		4	_aRC660 _b2019 EB
245	0	0	_aDiabetes Mellitus : _bA risk factor for Alzheimer's Disease _cedited by Yusaku Nakabeppu, Toshiharu Ninomiya.
264		1	_aSingapore _bSpringer International Publishing _c2019
300			_a1 recurso en línea (VI, 248 páginas) _b49 ilustraciones, 28 ilustraciones a color
337			_aelectrónico _bc
338			_arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aAdvances in Experimental Medicine and Biology _x0065-2598 _v1128
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aChapter 1 Origins of brain insulin and its function -- Chapter 2 Epidemiological evidence of the relationship between diabetes and dementia -- Chapter 3 Molecular pathophysiology of insulin depletion, mitochondrial dysfunction, and oxidative stress in Alzheimer's Disease Brain -- Chapter 4 The Full Spectrum of Alzheimer's Disease is Rooted in Metabolic -- Derangements That Drive Type 3 Diabetes -- Chapter 5 The roles of apolipoprotein E, lipids and glucose in the pathogenesis of Alzheimer's disease -- Chapter 6 Molecular connection between diabetes and dementia -- Chapter 7 Type II Diabetes mellitus accelerates age-dependent Ab pathology in cynomolgus monkey brain -- Chapter 8 Diabetes-related dementia -- Chapter 9 Tortuous paths of insulin signaling and mitochondria in Alzheimer's disease -- Chapter 10 Mammalian target of rapamycin at the crossroad between Alzheimer's Disease and diabetes -- Chapter 11 Therapeutic strategies for Alzheimer's disease in the view of diabetes mellitus.
520	3		_aThis book describes the precise mechanisms by which insulin resistance and diabetes mellitus (DM) act as risk factors for Alzheimer's disease (AD). It opens by discussing the de novo synthesis of insulin in the brain and its functional significance with regard to glucose metabolism and maintenance of neuronal function in the brain. The epidemiological evidence that DM is a risk factor for the development of dementia, including AD as well as vascular dementia, is then examined. Subsequent chapters explore in depth the mechanisms involved in this relationship, including abnormal protein processing, dysregulated glucose metabolism, impaired insulin signaling, and mitochondrial dysfunction. The molecular interactions between diabetes and AD are fully discussed, highlighting the pathological molecular mechanisms induced by diabetes that promote and accelerate AD pathology. Finally, diagnostic biomarkers and potential therapeutic approaches for AD are considered on the basis of the presented evidence. In providing answers to the critical questions of whether and why DM is a risk factor for AD, this book will hold appeal for a wide interdisciplinary audience.
988			_aPrimersemestre_2019_BiomedLife
650		7	_2embne _9138582 _aDiabetes
650		7	_2embne _aNeurología _9139040
650		7	_2embne _9144620 _aAlzheimer, Enfermedad de
700	1		_aNakabeppu, Yusaku. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aNinomiya, Toshiharu. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9789811335396
776	0	8	_iPrinted edition: _z9789811335419
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-13-3540-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _cm _dz _feng _ggw _h0 _b08/2019 _ek _zSI